Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
S2CID 6471940
Killion EA et al (2020) Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists
Retatrutide Activates GIP, GLP-1, and Glucagon Receptors Research suggests retatrutide functions as: A GLP-1 receptor agonist A glucagon receptor agonist A glucose-dependent insulinotropic polypeptide receptor agonist This multi-pathway receptor activity may influence: Glucose metabolism Energy expenditure Appetite signaling Glycemic control Endocrine pathways Overall metabolic regulation Retatrutide also activates GIP receptor pathways that researchers believe may contribute to improved metabolic signaling and weight management outcomes
The FDAs Cardiovascular and Renal Drugs Advisory Committee voted 9-3 that patisirans benefits outweigh its risks in this indication, despite concerns expressed in FDA briefing documents prior to the adcomm meeting
10.1016/0014-5793(89)81332-8 FEBS Lett
US$ 21.29
US$ 22.61
US$ 26.13
US$ 21.23
US$ 29.44
US$ 22.71
US$ 24.74
US$ 24.07
US$ 26.51
